BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 31290203)

  • 1. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
    Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
    Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
    Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
    Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
    Tancredi R; Furlanetto J; Loibl S
    Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.
    Shah AN; Metzger O; Bartlett CH; Liu Y; Huang X; Cristofanilli M
    Oncologist; 2020 Jun; 25(6):e900-e908. PubMed ID: 32176406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant for hormone-sensitive metastatic breast cancer.
    Lee CI; Goodwin A; Wilcken N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
    Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
    Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapy for Premenopausal Women with HR
    Bardia A; Hurvitz S
    Clin Cancer Res; 2018 Nov; 24(21):5206-5218. PubMed ID: 29884743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
    Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
    Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.